Modeling and Simulation - PK/PD Archives | Page 3 of 46 | Certara

Blog

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

CertaraMarch 3, 2026

Live Events

Phoenix Roadshow 2026 – Cambridge

CertaraMarch 2, 2026

Live Events

Phoenix Roadshow 2026 – Raleigh/Durham

CertaraMarch 2, 2026

Blog

Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

CertaraFebruary 27, 2026

Live Events

Phoenix Roadshow 2026 – Philadelphia

CertaraFebruary 27, 2026

On-Demand Webinar

Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit)

This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…

CertaraFebruary 27, 2026

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle PillsburyFebruary 23, 2026

Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

CertaraFebruary 23, 2026

Webinar

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

CertaraFebruary 23, 2026

On-Demand Webinar

Alternative parameters in NCA using Phoenix WinNonlin

Learn how to enhance formulation evaluation using Phoenix tools to calculate advanced PK parameters beyond…

CertaraFebruary 23, 2026

© 2026 Certara. All Rights Reserved. | Legal | Privacy policy